40Saranjit Singh, Skill Development and Pharmaceutical Education (invited article), APTI Bulletin, Vol 17, Issue 102, Jul – August, 2016, pp. 8-17.
39Saranjit Singh, Some Suggestions on Conduct of Sellable Drug Delivery Research in Academia, Journal of Pharmaceutical Sciences and Technology Management (NMIMS, Mumbai). 1 (2) 2015, 1-7
38Saranjit Singh, Quality by Design in Education (QbDE) – A Possible Futuristic Approach to Improve Current Status of Pharmaceutical Education in India (invited article), Indian Journal of Pharmaceutical Education and Research, 49 (4) (Suppl. 2) Oct-Dec, 2015.
37Saranjit Singh, Quality by Design in Education (QbDE) – A Possible Futuristic Approach to Improve Current Status of Pharmaceutical Education in India (invited article), APTI Bulletin, Vol 16, Issue 95, May – June, 2015, pp 3-7.
36Saranjit Singh, Including and Emphasizing Precautions in SOPs and STPs: An Often Missed/Neglected Opportunity to Communicate About Risks to Shop Floor and Laboratory Staff in the Pharmaceutical Industry, Pharma Review, Jan-Feb Issue, 13 (73) 63-65 (2015).
35H. Bhutani, M. Kurmi, Saranjit Singh, S. Beg, and B. Singh, Quality by Design in Analytical Sciences: An Overview, Pharmatimes, 46(8) 71-75 (2014).
34Saranjit Singh, An Update on World Health Organization’s Quality Guidelines, Souvenir, 63rd Indian Pharmaceutical Congress, Bangalore, 16-18 December 2011.
33Saranjit Singh, An Update on Recent Quality Related Requirements and Standards of WHO, Pharmacos, 36, 9-13 (2009). 
32Saranjit Singh, Indian Pharma 2009- Caution! Bumps Ahead! Chronical Pharmabiz, 60th IPC Special Supplement, December 11, 2008
31Saranjit Singh, Forensic Analysis of Compendial Articles, G.I.T. Laboratory Journal Europe, 11(3-4) 38-39 (2007).
30Saranjit Singh and Vijay Kumar, Recent Developments on Long-Term Stability Test Conditions, The Pharma Review, 5 (25) 61-64, 66-68 (2006).
29Saranjit Singh, Hemant Bhutani and T.T. Mariappan, Quality Problems of Anti-Tuberculosis Fixed-Dose Combinations (FDCs): A Way Forward, Indian Journal of Tuberculosis, 53(4) 201-205 (2006).
28Saranjit Singh, Anti-Tuberculosis Fixed-Dose Combinations (FDCs): Solving their Bioavailability and Stability Problems, Pharmatimes, 38 (1), 16-19 (2005).
27Vijay Kumar, Tarun Handa and Saranjit Singh, Impurities-A Source of Drug Candidates? Chronicle Pharmabiz, 12, 147-148 (2005).
26Saranjit Singh, Is Schedule P of the Drugs and Cosmetics Act 1940 relevant in the present times? Pharmatimes, 33 (7), 15-16 (2001).
25Saranjit Singh, Sanjay Garg and Arvind Bansal, The quality of pharmaceutical products exported from India and the soundness of the dossiers submitted by Indian drug manufacturers, Pharmatimes, 33 (5) 12-16 (2001).
24Saranjit Singh, Understanding the Veterinary ICH (VICH) Harmonisation Process, Pharmatimes, 32(11) 12-15 (2000).
23Saranjit Singh and Monika Bakshi, A Critical Review of the Changes Made in the Revised ICH Parent Drug Stability Guideline (Q1AR), and Impurity Guidelines (Q3AR and Q3BR), Pharmatimes, 32, 15-18 (2000).
22Saranjit Singh, EMEA/CPMP Guidance Documents, Pharmatimes, 32(2), 15-20(2000).
21Saranjit Singh, The ICH Process, Its Benefits and Implications, CRIPS, 1(1), 2- 7 (2000).
20Saranjit Singh and Sanjay Garg, Basic Understanding Series-Understanding Analytical Method Validation, Pharmatimes, 31, 15(1999).
19Saranjit Singh, EMEA/CPMP Guidelines, Eastern Pharmacist, 41(12), 47-51(1998).
18Saranjit Singh, Stability testing vs Shelf-life, IDMA Bulletin, 29(no. 43), 1042-1056(1998).
17Saranjit Singh, An Update on ICH Process, Eastern Pharmacist, 61 (no. 487), 43-48(1998).
16Saranjit Singh, ICH Guidelines – The Latest Developments, Eastern Pharmacist, 60 (no. 479), 41-42 (1997)
15Saranjit Singh, Drug Stability Guidelines for International Registration of Pharmaceuticals, Pharmatimes, 29(8), 29(1997).
14Saranjit Singh, Understanding the ICH Harmonisation Process, Eastern Pharmacist,  60(no.474), 21(1997).
13M. Gulati, S. Bajad, Saranjit Singh and K.S. Chopra, Liposomes and Their Pharmaceutical  Applications, Pharmacos, 32, 44 (1995)
12Saranjit Singh, The Problem, The solution, But? Souvenir, August Session of the Association of Pharma Technocrats, New Delhi, 1994. p.69
11Saranjit Singh, Drug Stability Testing Laboratory: Time to Change the Primitive Look,  Eastern Pharmacist, 37(no. 435) , 53 (1994)
10Saranjit   Singh, Blister Pack and  Print  Readability, Pharmatimes, 25(1), 8(1993).
9Saranjit Singh, Need for Framing Guidelines for Stability Testing of Pharmaceutical Products, Pharmatimes, 24(9), 27(1992).
8Saranjit Singh, Amend Rule 65(19) of the Drugs and Cosmetics Rules, 1945 to Include an Expiry Date Clause, Pharmatimes, 24(10), 25(1992).
7Saranjit Singh and Amarjit Singh, Dropper Hangers which can be Easily Constructed by the Students, Journal of Chemical Education, 66, 967(1989)
6Saranjit Singh and Amarjit Singh, A Simple Way to Increase Temperature Control Precision in Student Water/Oil Baths, Journal of Chemical Education, 65, 1095(1988)
5S.K.  Baveja, Saranjit Singh and Amarjit Singh, On Improvisation of Dissolution Rate Test Equipment,  Pharmatimes,  20(no. 9), 11(1988)
4Saranjit Singh, Drug Stability Determination Through Kinetic Studies, Eastern Pharmacist, 31(no. 365), 37(1988)
3Saranjit Singh, Stability Related Programmes During Drug Development, Eastern Pharmacist, 30(no. 360), 51(1987)
2Saranjit Singh and Amarjit Singh, Thermostatic Ovens and Baths for Stability Studies, Eastern Pharmacist, 30(no.356), 115(1987)
1Saranjit Singh, Future of Biopharmaceutics in India, Pharmacos, 27, 46(1978)
Scroll to Top